Erratum: Fathi AT, Blonquist TM, Hernandez D, Et Al. Cabozantinib Is Well Tolerated in Acute Myeloid Leukemia and Effectively Inhibits the Resistance-Conferring FLT3/tyrosine Kinase Domain/F691 Mutation. Cancer. 2018;124:306-314.

Cancer - United States
doi 10.1002/cncr.31325
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Wiley

Related search

FLT3-TKD Mutation in Childhood Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Tyrosine Kinase Inhibition in Acute Myeloid Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Tyrosine Kinase Inhibition Increases the Cell Surface Localization of FLT3-ITD and Enhances FLT3-directed Immunotherapy of Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

mTOR Signaling Is Activated by FLT3 Kinase and Promotes Survival of FLT3-mutated Acute Myeloid Leukemia Cells

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2010English

Rational for Targeting the Hedgehog Signalling Pathway in Acute Myeloid Leukemia With FLT3 Mutation

Annals of Translational Medicine
Medicine
2016English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Potent Co-Operation Between the NUP98-NSD1 Fusion and the FLT3-ITD Mutation in Acute Myeloid Leukemia Induction

Haematologica
Hematology
2014English

8-Chloro-Adenosine Activity in FLT3-ITD Acute Myeloid Leukemia

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2019English

The Evolving Role of FLT3 Inhibitors in Acute Myeloid Leukemia: Quizartinib and Beyond

Therapeutic Advances in Hematology
Hematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy